抗人血小板膜糖蛋白Ⅲa单克隆抗体抑制兔血栓形成的实验研究

目的　评价抗人血小板膜糖蛋白Ⅲa单克隆抗体SZ21抑制兔血栓形成的能力。方法不同浓度的SZ21（0、10及20μg／ml）分别加入兔富血小板血浆（PRP）中，进行二磷酸腺苷（ADP）诱导的兔血小板聚集试验；体内注射SZ21（1.5mg／kg），注射前及注射后5、30及60分钟时制备兔PRP，分别进行聚集试验；用颈动静脉旁路血栓模型研究SZ21对兔血栓形成的作用，20只新西兰兔随机分成4组，体内注射SZ21，剂量为A组0.1mg／kg，B组0.4mg／kg，C组0.75mg／kg，D为对照组（SZ391mg／kg），然后测定血栓重量。结果　体外20μg／ml的SZ21对兔血小板抑制率为80％；SZ21体内注射60分钟时完全抑制血小板聚集功能；血栓模型分组试验，各组平均栓重为A组31mg，B组21mg，C组20.2mg，D组31mg，B、C组与对照组间有明显统计学差异（P＜0.01）。结论　单克隆抗体SZ21能有效抑制兔动静脉旁路血栓形成。

The experimental research of inhibitory potency to rabbit thrombosis by McAb against human platelet membren glycoprotein

Objective　To evaluate the inhibitory potency of McAb SZ21 to thrombosis of rabbits．Methods　SZ21 was added of rabbit PRP at the final concentration of 0，10 and 20μg／ml．Aggregation test was induced by ADP；PRP was prepared before，and at 5，30 and 60min after infusion of SZ21（1.5mg／kg），then aggregation was tested．We evaluated the inhibitory potency of SZ21 to thrombosis of rabbits by the aid of A-V shunt thrombosis model．20 rabbits were divided into A，B，C and D groups randomly．The dose of SZ21 were：A， 0.1mg／kg；B，0.4mg／kg and C，0.75mg／kg，respectively．Group D was used as control （SZ39 1mg／kg）．The thrombus was weighed．Results　The inhibition rate of ADP （10μM） induced platelet aggregation was 80％ at 20μg／ml of SZ21 in vitro，and it could reach 100％ if SZ21 was infused in vivo at 1.5mg／kg after 1 hour．The thrombus weights of group B and C were significantly decreased compared with control （P＜0.01）．Conclusion　It is possible to inhibit platelet function by ex vivo or in vivo management with McAb SZ21．